Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK

Abstract

The results suggest that hypoglycaemia, weight change, gastrointestinal side effects and efficacy are of primary importance to patients in their OAD preferences in T2DM. These four attributes comprised over 80% of the RI.

The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus

“…However, as these agents have side effects (e.g., worsening hypoglycemia or weight gain, gastrointestinal side effects, and/or fluid retention), the use of combination therapies can further diminish overall tolerability [13]. These factors are of chief importance to patients with T2DM when selecting their preference for oral glucoselowering agents [15]. Given the persistent rise in the global prevalence of diabetes, with projections in excess of 590 million cases of diabetes within the next 25 years [16], coupled with the fact that T2DM accounts for 90 --95% of all cases of diabetes [1], there is a pressing need for new effective therapies for T2DM with improved safety and tolerability profiles.…”

Be Careful What You Ask For: Effects of Benefit Descriptions on Diabetes Patients’ Benefit-Risk Tradeoff Preferences

“…Our results support the latter explanation. As reported by others [14,23,24,26,27,29,30], respondents were in general found to be much more concerned about the risk of treatment than the benefit.…”

“…A number of stated-preference (SP) studies have been conducted to elicit the relative importance of different diabetes treatment aspects for patients [14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33]. This study contributes to this literature by evaluating the results of a randomized, discrete-choice experiment (DCE) that examined the effect of presenting respondents with technical terms versus pragmatic descriptions of similar treatment benefits on a patient's stated benefit-risk preferences for injectable diabetes treatment.…”

Experimentelle Präferenzmessung im Gesundheitswesen mit Hilfe von Best-Worst Scaling (BWS)

“…In dieser Funktion eröffnet BWS neue Optionen im Bereich der Gesundheits-und Versorgungsforschung. Eine solche Option ist die genauere Erfassung der Heterogenität von Präferenzen [6].…”

“…Für die Patienten stellt sich die Frage, ob die Verbesserung des Stoffwechsels das Risiko der Gewichtszunahme wert ist. Besonders wenn sie keine Erfahrungen mit Hypoglykämien (Unterzuckerungen) haben, könnten oral therapierte Patienten (OAD) im Unterschied zu insulinerfahrenen Patienten dazu nicht bereit sein [4,6].…”